OMER

Omeros Corporation

OMER, USA

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

https://www.omeros.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
OMER
stock
OMER

Wall Street Zen Upgrades Omeros (NASDAQ:OMER) to Hold MarketBeat

Read more →
OMER
stock
OMER

Omeros (NASDAQ:OMER) Trading Down 5.1% - Here's What Happened MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$28

Analyst Picks

Strong Buy

1

Buy

1

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-3.11

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Medium

14.02 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-16.65 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 47.30% of the total shares of Omeros Corporation

1.

BlackRock Inc

(5.9524%)

since

2025/06/30

2.

Ingalls & Snyder LLC

(5.8524%)

since

2025/06/30

3.

Vanguard Group Inc

(4.8248%)

since

2025/06/30

4.

Vanguard Total Stock Mkt Idx Inv

(2.491%)

since

2025/07/31

5.

D. E. Shaw & Co LP

(2.4207%)

since

2025/06/30

6.

Stifel Financial Corp

(2.2377%)

since

2025/06/30

7.

iShares Russell 2000 ETF

(2.0541%)

since

2025/08/31

8.

Geode Capital Management, LLC

(2.0129%)

since

2025/06/30

9.

Morgan Stanley - Brokerage Accounts

(1.9918%)

since

2025/06/30

10.

State Street Corp

(1.7634%)

since

2025/06/30

11.

UBS Group AG

(1.2762%)

since

2025/06/30

12.

Marshall Wace Asset Management Ltd

(1.0894%)

since

2025/06/30

13.

Two Sigma Investments LLC

(0.9848%)

since

2025/06/30

14.

Vanguard Institutional Extnd Mkt Idx Tr

(0.946%)

since

2025/07/31

15.

Bank of Montreal

(0.8392%)

since

2025/06/30

16.

BMO Capital Markets Corp.

(0.8392%)

since

2025/06/30

17.

Fidelity Small Cap Index

(0.8297%)

since

2025/06/30

18.

CI Private Wealth LLC

(0.7797%)

since

2025/06/30

19.

DeepCurrents Investment Group LLC

(0.776%)

since

2025/06/30

20.

Royal Bank of Canada

(0.7407%)

since

2025/06/30

21.

Northern Trust Corp

(0.7123%)

since

2025/06/30

22.

Charles Schwab Investment Management Inc

(0.7048%)

since

2025/06/30

23.

iShares Russell 2000 Growth ETF

(0.6363%)

since

2025/08/31

24.

Two Sigma Advisers, LLC

(0.6213%)

since

2025/06/30

25.

Renaissance Technologies Corp

(0.5623%)

since

2025/06/30

26.

Fidelity Extended Market Index

(0.4591%)

since

2025/07/31

27.

Schwab US Small-Cap ETFâ„¢

(0.41%)

since

2025/08/30

28.

Vanguard Russell 2000 ETF

(0.3952%)

since

2025/07/31

29.

State St Russell Sm Cap® Indx SL Cl I

(0.2789%)

since

2025/08/31

30.

Schwab Small Cap Index

(0.217%)

since

2025/07/31

31.

Vanguard US Momentum Factor ETF

(0.2023%)

since

2025/06/30

32.

NT R2000 Index Fund - NL

(0.2007%)

since

2025/06/30

33.

iShares Micro-Cap ETF

(0.188%)

since

2025/08/31

34.

Extended Equity Market Fund K

(0.1659%)

since

2025/06/30

35.

NT R2000 Index Fund - DC - NL - 3

(0.16%)

since

2025/06/30

36.

Fidelity Total Market Index

(0.1575%)

since

2025/07/31

37.

iShares Russell 2000 Small-Cap Idx Instl

(0.1418%)

since

2025/07/31

38.

Russell 2500â„¢ Index Fund F

(0.1368%)

since

2025/06/30

39.

SPDR® Russell 2000 US Small Cap ETF

(0.1294%)

since

2025/08/31

40.

Fidelity Series Total Market Index

(0.1201%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.4549

Latest Release

Date

2025-09-30

EPS Actual

-0.34

EPS Estimate

-0.45

EPS Difference

0.11

Surprise Percent

24.4444%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(0.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(1)
Value
Overpriced(1.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.